654 related articles for article (PubMed ID: 35961700)
1. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance.
Ravichandra A; Bhattacharjee S; Affò S
Adv Cancer Res; 2022; 156():201-226. PubMed ID: 35961700
[TBL] [Abstract][Full Text] [Related]
2. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase.
Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R
Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870
[TBL] [Abstract][Full Text] [Related]
3. SERPINE1: Role in Cholangiocarcinoma Progression and a Therapeutic Target in the Desmoplastic Microenvironment.
Czekay RP; Higgins CE; Aydin HB; Samarakoon R; Subasi NB; Higgins SP; Lee H; Higgins PJ
Cells; 2024 May; 13(10):. PubMed ID: 38786020
[TBL] [Abstract][Full Text] [Related]
4. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
[No Abstract] [Full Text] [Related]
5. Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of
Li JH; Wu X; Ni X; Li YX; Xu L; Hao XY; Zhao W; Zhu XX; Yin XY
Clin Transl Med; 2023 Mar; 13(3):e1213. PubMed ID: 36855786
[TBL] [Abstract][Full Text] [Related]
6. Cancer-Associated Fibroblasts in Hepatocellular Carcinoma and Cholangiocarcinoma.
Ying F; Chan MSM; Lee TKW
Cell Mol Gastroenterol Hepatol; 2023; 15(4):985-999. PubMed ID: 36708970
[TBL] [Abstract][Full Text] [Related]
7. HS6ST1 overexpressed in cancer-associated fibroblast and inhibited cholangiocarcinoma progression.
Hu S; Xia C; Zou H; Ren W; Liu L; Wang L; Kang Q; He K; Wang T; Zhang X
Dig Liver Dis; 2023 Aug; 55(8):1114-1125. PubMed ID: 36586771
[TBL] [Abstract][Full Text] [Related]
8. Matricellular proteins in intrahepatic cholangiocarcinoma.
Sirica AE
Adv Cancer Res; 2022; 156():249-281. PubMed ID: 35961702
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
[TBL] [Abstract][Full Text] [Related]
10. Crenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition.
Mancarella S; Gigante I; Serino G; Pizzuto E; Dituri F; Valentini MF; Wang J; Chen X; Armentano R; Calvisi DF; Giannelli G
J Exp Clin Cancer Res; 2022 Nov; 41(1):331. PubMed ID: 36443822
[TBL] [Abstract][Full Text] [Related]
11. Zinc Finger E-Box Binding Homeobox 1 Promotes Cholangiocarcinoma Progression Through Tumor Dedifferentiation and Tumor-Stroma Paracrine Signaling.
Lobe C; Vallette M; Arbelaiz A; Gonzalez-Sanchez E; Izquierdo L; Pellat A; Guedj N; Louis C; Paradis V; Banales JM; Coulouarn C; Housset C; Vaquero J; Fouassier L
Hepatology; 2021 Dec; 74(6):3194-3212. PubMed ID: 34297412
[TBL] [Abstract][Full Text] [Related]
12. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations.
Affo S; Nair A; Brundu F; Ravichandra A; Bhattacharjee S; Matsuda M; Chin L; Filliol A; Wen W; Song X; Decker A; Worley J; Caviglia JM; Yu L; Yin D; Saito Y; Savage T; Wells RG; Mack M; Zender L; Arpaia N; Remotti HE; Rabadan R; Sims P; Leblond AL; Weber A; Riener MO; Stockwell BR; Gaublomme J; Llovet JM; Kalluri R; Michalopoulos GK; Seki E; Sia D; Chen X; Califano A; Schwabe RF
Cancer Cell; 2021 Jun; 39(6):866-882.e11. PubMed ID: 33930309
[TBL] [Abstract][Full Text] [Related]
13. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?
Wang J; Loeuillard E; Gores GJ; Ilyas SI
Expert Opin Ther Targets; 2021 Oct; 25(10):835-845. PubMed ID: 34806500
[TBL] [Abstract][Full Text] [Related]
14. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated Fibroblasts and Extracellular Matrix: Therapeutical Strategies for Modulating the Cholangiocarcinoma Microenvironment.
Minini M; Fouassier L
Curr Oncol; 2023 Apr; 30(4):4185-4196. PubMed ID: 37185432
[TBL] [Abstract][Full Text] [Related]
16. Integrative analyses of bulk and single-cell transcriptomics reveals the infiltration and crosstalk of cancer-associated fibroblasts as a novel predictor for prognosis and microenvironment remodeling in intrahepatic cholangiocarcinoma.
Zhong YJ; Luo XM; Liu F; He ZQ; Yang SQ; Ma WJ; Wang JK; Dai YS; Zou RQ; Hu YF; Lv TR; Li FY; Hu HJ
J Transl Med; 2024 May; 22(1):422. PubMed ID: 38702814
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S
Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts: Versatile mediators in remodeling the tumor microenvironment.
Zhang Q; Wang Y; Liu F
Cell Signal; 2023 Mar; 103():110567. PubMed ID: 36538999
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma.
Mertens JC; Fingas CD; Christensen JD; Smoot RL; Bronk SF; Werneburg NW; Gustafson MP; Dietz AB; Roberts LR; Sirica AE; Gores GJ
Cancer Res; 2013 Jan; 73(2):897-907. PubMed ID: 23221385
[TBL] [Abstract][Full Text] [Related]
20. Modulating PCGF4/BMI1 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma.
Hu J; Xu H; Ma X; Bai M; Zhou Y; Miao R; Wang F; Li X; Cheng B
Am J Pathol; 2024 Jul; 194(7):1388-1404. PubMed ID: 38670529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
